All over the world, human beings have been looking for the "code" to obtain "organ regeneration". With the continuous scientific breakthroughs in the field of stem cell transplantation by modern biotechnology, these once unattainable dreams of self-replication and self-repair may soon come into reality. As the "seed" of human development, stem cells are a type of primitive cells that are very rare in number but have self-renewal and self-replication capabilities. They are the basis for the development and regeneration of tissues and organs. Adult stem cells (stem cells) and their progenitors with regenerative functions, progenitors, that exist in various tissues and organs can help the body repair various damages.
Biomedical circles all over the world have poured great enthusiasm and a lot of money into stem cell research including organ regeneration. Existing regenerative medicine therapies have already supported a huge market. According to data from Polaris Market Research, the regenerative medicine market was only 14.76 billion US dollars in 2017, but by 2026 this figure will reach 79.23 billion US dollars (about 504.47 billion yuan), and the growth rate is still increasing.
However, there are not many projects that actually apply stem cell technology to clinical medicine. Although researchers from various countries are also trying to cultivate hearts and kidneys, most of them are still in the laboratory stage, and it is difficult to scale up and commercialize. At present, Jimmy Ruisheng is the leading company in this field in China.
Regend Therapeutics｜Regend Therapeutics
Regend Therapeutics aims to "recreate life, reshape health", focuses on the field of human organ regenerative medicine from precursor cells, and seeks regenerative medicine solutions for clinical needs that cannot be met by traditional treatments.
The epithelial tissue precursor cell technology (referred to as "R-Clone technology") owned by the group is domestically pioneered and internationally leading. This unique technology has formed a common technology platform with multiple technical barriers consisting of micro-tissue separation, special medium formulation, trophoblast cell purification, in vitro bioefficacy testing, and non-refrigerated transportation. The sources of precursor cells that have been successfully realized include liver, lung, trachea, esophagus, stomach, intestinal tract, uterus, prostate, pancreas, ovary, etc.
A number of scientific research achievements of the group's R&D team have been published in internationally renowned academic journals such as Nature, Cell, Protein&Cell, and have more than ten core patents. The lung precursor cell REGEND001 cell preparation independently developed by the group is the world's first First-in-class new drug and is currently the only lung regenerative medicine product . Its active ingredient is derived from a type of bronchial basal layer cells isolated from the healthy airway of the patient's own lungs. It has the activity of adult stem cells and can differentiate into mature lung tissue cells, regenerate and repair alveolar and bronchial epithelial tissues. Therefore, it has good prospects for treating a variety of major respiratory diseases. At present, it has obtained two clinical trial approvals from the State Food and Drug Administration, and is conducting phase 1 and phase 2 registration clinical trials.
Regenerative-Clone technology platform
From the perspective of global biomedical development trends, cell and gene therapy (CGT) is a well-deserved hot spot in the next stage. Zuo Wei, the founder and chief scientist of Jimei Ruisheng, and professor of Tongji University School of Medicine, said: "In addition to helping patients restore 'normal' organ functions such as lungs and kidneys, combined with the R-Clone platform and genetic engineering technology, we are committed to using genetic technology to help patients obtain 'enhanced' organ functions, such as lungs with super anti-infection ability and kidneys with super hematopoietic ability. This is a field with abundant plants, and the space for future development is almost unlimited."
Tansi Biomedical Live Class
Focusing on the research and development of new drugs for lung and kidney precursor cells, this issue of T-Bio Tansi Biomedical Live Course organized by Tansi Biotech specially invited Dr. Zhang Ting, the founder and CEO of Jimmy Ruisheng Company, to bring you a wonderful sharing on "New Drug Development of Lung Precursor Cells in the Post-COVID-19 Era" at 19:30-20 : 30 on April 13 . In this live broadcast, Dr. Zhang Ting will introduce the process and some results of the world's first First-in-class new drug precursor cell preparation REGEND001 from discovery to product clinical trials, and also briefly introduce the research and development progress of renal precursor cell products.
★ 【Guest profile】
Zhang Ting, founder and CEO of Regend Therapeutics, professor-level senior engineer. Ph.D. from Tsinghua University, double degree in biology/computer science. He has successively engaged in scientific research and new drug development at the University of California, San Diego (UCSD), Sanford-Burnham Medical Institute and the Singapore Agency for Science and Technology (A*STAR), and served as the project leader of Johnson & Johnson. He has published a number of academic papers in top international journals such as Nature, Mol Cell, and EMBO, and won the second prize of Jiangsu Medical Science and Technology Progress Award. Elected as Suzhou Leading Talent, Zhejiang Qianjiang Talent and other titles. Served as the vice president of the Federation of Entrepreneurs of the Jiangxi Nanchang National High-tech Zone, the director of the Alumni Association of Yihong Business School of Shenyang Pharmaceutical University, and the entrepreneurial mentor of Xi'an Jiaotong-Liverpool University.
★ 【Speech Theme】
New Drug Development of Lung Precursor Cells in the Post-COVID-19 Era
★ 【Live Time】
April 13th 19:30-20:30
★ 【Speech Summary】
Irreversible damage to organs caused by factors such as viruses, environmental pollution, genetics, and other diseases has always been a major medical problem that plagues human beings. The rare precursor cells present in organs have the powerful function of regenerating organs and repairing organ damage. The R-Clone technology independently developed by Jimei Ruisheng prepares clinical-grade drugs by cultivating lung and kidney precursor cells to treat major refractory diseases including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis, and diabetic nephropathy. At present, REGEND001, the world's first innovative drug, has obtained two clinical trial approvals from the National Medical Products Administration, and is in the phase 1 and phase 2 registration clinical trials. The report will introduce the process and some results of the product from discovery to clinical trials, and also briefly introduce the research and development progress of renal precursor cell products.
★ 【Participation method】
Add WeChat TaasLabs-Bio Free Registration
Report/Feedback